drugset / Trial / NCT03643627
A Study of SYNT001 in Healthy Volunteers
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is being done to compare the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of an intravenous (IV) formulation of SYNT001. This is the first-in-human (FIH) study of SYNT001.
Timeline
- Start
- 2016-08-17
- Primary completion
- 2017-04-13
- Completion
- 2017-04-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ORILANOLIMAB | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | ORILANOLIMAB | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | ORILANOLIMAB | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | ORILANOLIMAB | Monoclonal antibody | 30 mg/kg | Intravenous |
Indications
No indication recorded.